The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SAVA | -87.37% | -60.29% | -16.85% | -96% |
| S&P | +19.89% | +109.18% | +15.89% | +353% |
Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.
Without admitting wrongdoing, the company put a regulatory controversy to rest, but this was expensive.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.20M | 33.3% |
| Market Cap | $87.44M | -85.2% |
| Market Cap / Employee | $2.91M | 0.0% |
| Employees | 30 | 3.4% |
| Net Income | -$44.22M | -818.5% |
| EBITDA | -$45.19M | 32.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $112.38M | -45.8% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -65.00% | -58.0% |
| Return On Invested Capital | -28.11% | 0.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$4.95M | 72.9% |
| Operating Free Cash Flow | -$4.95M | 72.9% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 8.47 | 0.68 | 0.50 | 0.69 | -89.92% |
| Price to Tangible Book Value | 8.48 | 0.68 | 0.50 | 0.69 | -89.93% |
| Enterprise Value to EBITDA | -38.87 | 0.52 | 1.84 | 0.55 | -110.16% |
| Return on Equity | -11.0% | -17.2% | -70.6% | -88.9% | 965.62% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
